Research programme: interferon beta - HanAll Biopharma

Drug Profile

Research programme: interferon beta - HanAll Biopharma

Alternative Names: HL144; Interferon-beta - HanAll Biopharma

Latest Information Update: 11 Mar 2011

Price : $50

At a glance

  • Originator Nautilus Biotech
  • Developer HanAll Biopharma
  • Class Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 11 Mar 2011 No development reported - Preclinical for Multiple sclerosis in South Korea (SC)
  • 21 Sep 2010 Research programme: interferon beta - HanAll Pharmaceutical is available for licensing (www.hanallbiopharma.com)
  • 20 Jul 2004 This programme is available for licensing (http://www.nautilusbiotech.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top